Literature DB >> 24695620

The Use of Antibodies in Small-Molecule Drug Discovery.

Catherine J Marsden1, Sonia Eckersley2, Max Hebditch2, Alexander J Kvist2, Roy Milner2, Danielle Mitchell2, Juli Warwicker2, Anna E Marley2.   

Abstract

Antibodies are powerful research tools that can be used in many areas of biology to probe, measure, and perturb various biological structures. Successful drug discovery is dependent on the correct identification of a target implicated in disease, coupled with the successful selection, optimization, and development of a candidate drug. Because of their specific binding characteristics, with regard to specificity, affinity, and avidity, coupled with their amenability to protein engineering, antibodies have become a key tool in drug discovery, enabling the quantification, localization, and modulation of proteins of interest. This review summarizes the application of antibodies and other protein affinity reagents as specific research tools within the drug discovery process.
© 2014 Society for Laboratory Automation and Screening.

Keywords:  antibody tool; crystallization chaperone; drug discovery; phenotypic screening; review; target validation

Mesh:

Substances:

Year:  2014        PMID: 24695620     DOI: 10.1177/1087057114527770

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  6 in total

1.  Proteomics for cancer drug design.

Authors:  Amanda Haymond; Justin B Davis; Virginia Espina
Journal:  Expert Rev Proteomics       Date:  2019-08-04       Impact factor: 3.940

2.  Claudin-2 Expression Levels in Ulcerative Colitis: Development and Validation of an In-Situ Hybridisation Assay for Therapeutic Studies.

Authors:  Kevin Randall; Neil Henderson; Jaimini Reens; Sonia Eckersley; Ann-Christin Nyström; Marie C South; Clare A Balendran; Gerhard Böttcher; Glen Hughes; Sally A Price
Journal:  PLoS One       Date:  2016-09-06       Impact factor: 3.240

3.  EMMPRIN-Targeted Magnetic Nanoparticles for In Vivo Visualization and Regression of Acute Myocardial Infarction.

Authors:  Irene Cuadrado; Maria Jose Garcia Miguel Piedras; Irene Herruzo; Maria Del Carmen Turpin; Borja Castejón; Paula Reventun; Ana Martin; Marta Saura; Jose Luis Zamorano; Carlos Zaragoza
Journal:  Theranostics       Date:  2016-02-15       Impact factor: 11.556

4.  Sequence composition predicts immunoglobulin superfamily members that could share the intrinsically disordered properties of antibody CH1 domains.

Authors:  Max Hebditch; Robin Curtis; Jim Warwicker
Journal:  Sci Rep       Date:  2017-09-29       Impact factor: 4.379

5.  Non-Invasive Detection of Extracellular Matrix Metalloproteinase Inducer EMMPRIN, a New Therapeutic Target against Atherosclerosis, Inhibited by Endothelial Nitric Oxide.

Authors:  Rafael Ramirez-Carracedo; Laura Tesoro; Ignacio Hernandez; Javier Diez-Mata; Marco Filice; Rocío Toro; Manuel Rodriguez-Piñero; Jose Luis Zamorano; Marta Saura; Carlos Zaragoza
Journal:  Int J Mol Sci       Date:  2018-10-19       Impact factor: 5.923

Review 6.  Improving target assessment in biomedical research: the GOT-IT recommendations.

Authors:  Christoph H Emmerich; Lorena Martinez Gamboa; Martine C J Hofmann; Marc Bonin-Andresen; Olga Arbach; Pascal Schendel; Björn Gerlach; Katja Hempel; Anton Bespalov; Ulrich Dirnagl; Michael J Parnham
Journal:  Nat Rev Drug Discov       Date:  2020-11-16       Impact factor: 112.288

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.